Literature DB >> 7851278

A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids.

L J Cheskin1, P J Fudala, R E Johnson.   

Abstract

We compared the short-term efficacy of a high-dose, 3 day regimen of buprenorphine to a standard 5-day course of clonidine in attenuating the signs and symptoms of the acute opioid abstinence syndrome during rapid detoxification from heroin in 25 men and women admitted to a closed inpatient research ward for this randomized, double-blind, parallel-group trial. Among the 18 completers, there were no significant differences between the buprenorphine and clonidine groups on five subjective and six physiological measures. However, clonidine lowered blood pressure and buprenorphine provided more effective early relief of withdrawal symptoms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7851278     DOI: 10.1016/0376-8716(94)90093-0

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  23 in total

1.  [Withdrawal in a patient with an implantable drug delivery system in spite of continuation of opiate therapy].

Authors:  S Lochner; U Heinrich-Gräfe; W Kirch
Journal:  Internist (Berl)       Date:  2010-05       Impact factor: 0.743

2.  Characterizing opioid withdrawal during double-blind buprenorphine detoxification.

Authors:  Kelly E Dunn; Kathryn A Saulsgiver; Mollie E Miller; Paul A Nuzzo; Stacey C Sigmon
Journal:  Drug Alcohol Depend       Date:  2015-03-12       Impact factor: 4.492

3.  A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Authors:  Walter Ling; Leslie Amass; Steve Shoptaw; Jeffrey J Annon; Maureen Hillhouse; Dean Babcock; Greg Brigham; Judy Harrer; Malcolm Reid; Joan Muir; Betty Buchan; Debbie Orr; George Woody; Jonathan Krejci; Douglas Ziedonis
Journal:  Addiction       Date:  2005-08       Impact factor: 6.526

Review 4.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

5.  Comparative trial to study the effectiveness of clonidine hydrochloride and buprenorphine-naloxone in opioid withdrawal - a hospital based study.

Authors:  Syed Sajad Hussain; Samina Farhat; Yasir Hassan Rather; Zaffar Abbas
Journal:  J Clin Diagn Res       Date:  2015-01-01

6.  Buprenorphine abuse in India : an update.

Authors:  Y Sharma; S K Mattoo
Journal:  Indian J Psychiatry       Date:  1999-04       Impact factor: 1.759

Review 7.  Treatment of heroin (diamorphine) addiction: current approaches and future prospects.

Authors:  Gerardo Gonzalez; Alison Oliveto; Thomas R Kosten
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Authors:  Leslie Amass; Walter Ling; Thomas E Freese; Chris Reiber; Jeffrey J Annon; Allan J Cohen; Dennis McCarty; Malcolm S Reid; Lawrence S Brown; Cynthia Clark; Douglas M Ziedonis; Jonathan Krejci; Susan Stine; Theresa Winhusen; Greg Brigham; Dean Babcock; Joan A Muir; Betty J Buchan; Terry Horton
Journal:  Am J Addict       Date:  2004

Review 9.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03

10.  The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification.

Authors:  Laura Sheard; Nat M J Wright; Clive E Adams; Nicole Bound; Bruno Rushforth; Roger Hart; Charlotte N E Tompkins
Journal:  Trials       Date:  2009-07-14       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.